Жукова Людмила Григорьевна

BCD-178-2^{ClinicalTrials.gov}

Clinical Study of the Efficacy and Safety of BCD-178 and Perjeta® as Neoadjuvant Therapy of HER2-Positive Breast Cancer

Статус:	Recruiting
Фаза:	Phase 3
Начало:	30 января 2023 г.
Окончание:	31 января 2026 г.
Описание:	The goal of this study is to compare the efficacy and safety of BCD-178 and Perjeta as neoadjuvant therapy for HER2-positive breast cancer. Subjects with histologically confirmed diagnosis of HER2-positive invasive breast cancer (stage II-III, tumor size > 2 cm), with no estrogen (ER) and progesterone (PR) receptors will be randomized to one of two treatment groups (BCD-178 group or Perjeta group) in a 1:1 ratio.
	смотреть на ClinicalTrials.gov

DS_v01^{ClinicalTrials.gov}

A Multicenter Prospective Post-registration Study of Empegfilgrastim to Evaluate Safety and Efficacy in Special Cancer Populations

Статус:	Unknown status
Фаза:	не указано
Начало:	28 апреля 2020 г.
Окончание:	1 сентября 2023 г.
Описание:	This study was designed to evaluate the efficacy and safety of Extimia® (INN - empegfilgrastim) in reducing the frequency, duration of neutropenia, the incidence of febrile neutropenia and infections caused by febrile neutropenia in patients with High and "Gray Zone" Risk Reccurrence Breast Cancer, Gastointestinal Cancers and Gynecological Malignancies
	смотреть на ClinicalTrials.gov

BCD-100-5^{ClinicalTrials.gov}

Efficacy and Safety of BCD-100 (Anti-PD-1) in Combination With Platinum-Based Chemotherapy With and Without Bevacizumab as First-Line Treatment of Subjects With Advanced Cervical Cancer (FERMATA)

Статус:	Unknown status
Фаза:	Phase 3
Начало:	1 октября 2019 г.
Окончание:	1 декабря 2024 г.
Описание:	This is a randomized, multicenter, double-blind, Phase 3 study of efficacy and safety of BCD-100 plus platinum-based chemotherapy with and without bevacizumab versus placebo plus platinum-based chemotherapy with and without bevacizumab
	смотреть на ClinicalTrials.gov

BCD-100-4/CAESURA^{ClinicalTrials.gov}

Efficacy and Safety of BCD-100 (Anti-PD-1) in Combination With Platinum-Based Chemotherapy and Bevacizumab in Patients With Recurrent, Persistent or Metastatic Cervical Cancer (CAESURA)

^ГРЛС Многоцентровое открытое несравнительное исследование эффективности и безопасности препарата BCD-100 (ЗАО «БИОКАД», Россия) в комбинации с платиносодержащей химиотерапией и бевацизумабом в терапии первой линии у пациенток с рецидивирующим/персистирующим либо метастатическим раком шейки матки

Статус:	Unknown status
Фаза:	Phase 2
Начало:	25 декабря 2018 г.
Окончание:	7 июля 2020 г.
Описание:	This is a multicenter, open-label, single-arm study of efficacy, safety and pharmacokinetics of BCD-100 (JSC BIOCAD, Russia) in combination with platinum-based chemotherapy and bevacizumab as first-line treatment in patients with recurrent/persistent or metastatic cervical cancer.
	смотреть на ClinicalTrials.gov

BCD-178-2 ClinicalTrials.gov